- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q2 2026 | 157 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 August 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the second quarter of 2026. The report is available on the company's... ► Artikel lesen | |
| 28.05. | Modus Therapeutics Holding AB: Annual General Meeting in Modus Therapeutics Holding AB (publ) | 186 | GlobeNewswire (Europe) | Modus Therapeutics' Annual General Meeting on 28 May 2026 resolved in accordance with the following:
That no dividend would be paid.To discharge the board members and the managing director from liability... ► Artikel lesen | |
| 26.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for Q1 2026 | 191 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 May 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes its interim report for the first quarter of 2026. The report is available on the company's website... ► Artikel lesen | |
| 25.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 811 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 337 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 545 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 333 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 359 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,695 | -4,51 % | Aktuell zu Ihren Aktien: NanoRepro | Bis an die 200-Tage-Durchschnittslinie ist der Aktienkurs von NanoRepro zurückgefallen. Gemessen am Juli-Hoch entspricht das einem Minus von rund 25 Prozent an Börsenwert. Die wesentlichen Ursachen... ► Artikel lesen | |
| MARINOMED BIOTECH | 4,200 | 0,00 % | Marinomed: Rating und Kursziel ausgesetzt | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC befindet sich die Marinomed Biotech AG seit dem 23. Juli in einem Sanierungsverfahren ohne Eigenverwaltung, nachdem Unither... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,149 | 0,00 % | Replenish Nutrients: SRC's Proposed $15M Strategic Investment Supports a 5x Step-Up in Owned Capacity | Company: Replenish NutrientsListings: CSE Canada, Frankfurt and US OTCTickers: ERTH / VVIVF / WIMNMarket cap at time of publication: $38 MCADStock price at time... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,055 | -3,63 % | Sana Biotechnology: Zwei Schlüsselprogramme nähern sich klinischen Studien | ||
| NOVABRIDGE BIOSCIENCES | 1,440 | -4,64 % | NovaBridge Biosciences: NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director | Martin Dewhurst appointed as independent director and member of the Audit and Compensation CommitteesVeteran healthcare executive brings more than 30 years of leadership, governance, and strategic... ► Artikel lesen | |
| GENEURO | 0,027 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.05.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 18.05.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.05.2026ISIN NameAU0000248288 ADELONG... ► Artikel lesen | |
| ERASCA | 16,030 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,360 | -2,75 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,060 | -5,89 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -3,36 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 118,49 | +2,65 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| BEAM THERAPEUTICS | 24,200 | -3,87 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,050 | +2,04 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| COGENT BIOSCIENCES | 33,650 | -1,46 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
MODUS THERAPEUTICS HOLDING AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,44 % bei einem Aktienkurs von 0,026 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.